Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system

Biomaterials

Volumn 33, Issue 21, 2012, Pages 5431-5440

  Hou, Lin ^a,b   Yao, Jing ^a   Zhou, Jianping ^a   Zhang, Qiang ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Combination therapy; Conjugates; Low molecular weight heparin; Paclitaxel; Retinoid acid; Self assembled nanoparticles

Indexed keywords

COMBINATION THERAPY; CONJUGATES; LOW-MOLECULAR WEIGHT HEPARINS; PACLITAXEL; SELF ASSEMBLED NANOPARTICLES;

CHEMOTHERAPY; DRUG DELIVERY; MOLECULAR WEIGHT; POLYSACCHARIDES; TUMORS;

NANOPARTICLES;

FLUORESCENT DYE; LOW MOLECULAR WEIGHT HEPARIN; NANOPARTICLE; NEAR INFRARED FLUORESCENT DYE; PACLITAXEL; RETINOIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CELL ENCAPSULATION; CELL NUCLEUS; CELL TRANSPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; INTERNALIZATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MICE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NEOPLASMS; PACLITAXEL; PARTICLE SIZE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TRETINOIN; TUMOR BURDEN; WHOLE BODY IMAGING;

MUS;

EID: 84860921054     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.070     Document Type: Article

References (45)

1. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903-2909.
2. Bae Y., Diezi T.A., Zhao A., Kwon G.S. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release 2007, 122:324-330.
3. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
4. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
5. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999, 5:83-94.
6. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H., Schot M., Mandjes I.A., Zurlo M.G., et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001, 12:315-323.
7. Segal E., Satchi-Fainaro R. Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev 2009, 61:1159-1176.
8. Dosio F., Brusa P., Crosasso P., Arpicco S., Cattel L. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J Control Release 1997, 47:293-304.
9. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 1997, 337:688-698.
10. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008, 122:743-752.
11. Bae K.H., Mok H., Park T.G. Synthesis, characterization, and intracellular delivery of reducible heparin nanogels for apoptotic cell death. Biomaterials 2008, 29:3376-3383.
12. Bae K.H., Moon C.W., Lee Y., Park T.G. Intracellular delivery of heparin complexed with chitosan-g-poly(ethylene glycol) for inducing apoptosis. Pharm Res 2009, 26:93-100.
13. Han H.D., Lee A., Song C.K., Hwang T., Seong H., Lee C.O., et al. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Pharm 2006, 313:181-188.
14. Wang Y., Xin D., Liu K., Zhu M., Xiang J. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 2009, 20:2214-2221.
15. Park K., Lee G.Y., Park R.W., Kim I.S., Kim S.Y., Byun Y. Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma. Pharm Res 2008, 25:268-276.
16. Smorenburg S.M., Van Noorden C.J. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001, 53:93-105.
17. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
18. Ortiz M.A., Bayon Y., Lopez-Hernandez F.J., Piedrafita F.J. Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. Drug Resist Updat 2002, 5:162-175.
19. Karmakar S., Banik N.L., Ray S.K. Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer 2008, 112:596-607.
20. Park K.M., Kang H.C., Cho J.K., Chung I.J., Cho S.H., Bae Y.H., et al. All-trans-retinoic acid (ATRA)-grafted polymeric gene carriers for nuclear translocation and cell growth control. Biomaterials 2009, 30:2642-2652.
21. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733.
22. Sessler R.J., Noy N. A ligand-activated nuclear localization signal in cellular retinoic acid binding protein-II. Mol Cell 2005, 18:343-353.
23. Hou L., Fan Y., Yao J., Zhou J., Li C., Fang Z., et al. Low molecular weight heparin-all-trans-retinoid acid conjugate as a drug carrier for combination cancer chemotherapy of paclitaxel and all-trans-retinoid acid. Carbohydr Polym 2011, 86:1157-1166.
24. Lee Y., Moon H.T., Byun Y. Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Thromb Res 1998, 92:149-156.
25. Hou L., Yao J., Zhou J. Simultaneous LC-MS analysis of paclitaxel and retinoic acid in plasma and tissues from tumor-bearing mice. Chromatographia 2011, 73:471-480.
26. Sato H., Wang Y.M., Adachi I., Horikoshi I. Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Biol Pharm Bull 1996, 19:1596-1601.
27. Kohane D.S. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 2007, 96:203-209.
28. Bastien J., Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004, 328:1-16.
29. Liu Z., Zhang Z., Zhou C., Jiao Y. Hydrophobic modifications of cationic polymers for gene delivery. Prog Polym Sci 2010, 35:1144-1162.
30. Andre N., Braguer D., Brasseur G., Goncalves A., Lemesle-Meunier D., Guise S., et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000, 60:5349-5353.
31. Kidd J.F., Pilkington M.F., Schell M.J., Fogarty K.E., Skepper J.N., Taylor C.W., et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem 2002, 277:6504-6510.
32. Yao H.J., Ju R.J., Wang X.X., Zhang Y., Li R.J., Yu Y., et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011, 32:3285-3302.
33. Cho Y.W., Park S.A., Han T.H., Son D.H., Park J.S., Oh S.J., et al. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 2007, 28:1236-1247.
34. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
35. Lee J.Y., Bae K.H., Kim J.S., Nam Y.S., Park T.G. Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA-multi-armed PEG nanocapsules. Biomaterials 2011, 32:8635-8644.
36. Liu J., Jiang Z., Zhang S., Saltzman W.M. Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials 2009, 30:5707-5719.
37. Rowinsky E.K., Donehower R.C. The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 1993, 20:16-25.
38. Xiao K., Luo J., Fowler W.L., Li Y., Lee J.S., Xing L., et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 2009, 30:6006-6016.
39. Barenholz Y., Amselem S., Goren D., Cohen R., Gelvan D., Samuni A., et al. Stability of liposomal doxorubicin formulations: problems and prospects. Med Res Rev 1993, 13:449-491.
40. Esmaeili F., Dinarvand R., Ghahremani M.H., Amini M., Rouhani H., Sepehri N., et al. Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci 2009, 98:2718-2730.
41. Muindi J.R. Retinoids in clinical cancer therapy. Cancer Treat Res 1996, 87:305-342.
42. Pratt M.A., Niu M.Y., Renart L.I. Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells. Apoptosis 2006, 11:589-605.
43. Park K., Kim Y.S., Lee G.Y., Nam J.O., Lee S.K., Park R.W., et al. Antiangiogenic effect of bile acid acylated heparin derivative. Pharm Res 2007, 24:176-185.
44. Wang X., Li J., Wang Y., Cho K.J., Kim G., Gjyrezi A., et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 2009, 3:3165-3174.
45. Kim S.C., Kim D.W., Shim Y.H., Bang J.S., Oh H.S., Wan Kim S., et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001, 72:191-202.